According to Acumen Research & Consulting, the global Intravenous Immunoglobulin Market was valued USD 11.8 Billion in 2022 and is estimated to be worth USD 24.4 Billion by 2032, rising at a CAGR of 7.6% over the forecast period

The intravenous immunoglobulin (IVIG) industry is a subset of the biopharmaceutical industry that focuses on the manufacture, distribution, and usage of IVIG medicines. IVIG is a blood-derived substance that contains concentrated antibodies and is injected intravenously to treat a variety of medical disorders. Because of the rising frequency of immunodeficiency illnesses, autoimmune diseases, and neurological ailments, the sector has grown significantly. IVIG is used to treat primary immunodeficiency illnesses, autoimmune disorders, and a variety of other problems. Factors such as the ageing population, innovations in manufacturing techniques, and increasing awareness among healthcare professionals are driving the intravenous immunoglobulin (IVIG) market.

Human plasma collected through plasmapheresis or pooled plasma donations is used to make IVIG products. To get a highly pure immunoglobulin product, the manufacturing method includes purification, viral inactivation, and fractionation. IVIG is manufactured by a number of pharmaceutical businesses, both worldwide and regional. To assure the safety and efficacy of their goods, these firms follow tight regulatory requirements and quality standards.

Intravenous Immunoglobulin Market Statistics

• With a 7.6% CAGR (2023-2032), the global intravenous immunoglobulin market revenue is expected to reach USD 11.8 billion in 2022
• North America accounted for more than 47% of the intravenous immunoglobulin (IVIG) market share in 2022
• The Asia-Pacific intravenous immunoglobulin (IVIG) market growth is expected to grow at a CAGR of more than 8% between 2023 and 2032
• The immunodeficiency illnesses application accounted for more than 24% of the market in 2022
• The hospital pharmacy accounted for US$ 6.8 billion in 2022
• Expansion of indications and therapeutic applications are the new Intravenous Immunoglobulin market trend.

Request for a sample of this premium research report@ https://www.acumenresearchandconsulting.com/request-sample/3269

Intravenous Immunoglobulin Market Dynamics

Increasing Prevalence of Immunodeficiency Disorders and Autoimmune Diseases Fuels the Intravenous Immunoglobulin (IVIG) Market Value

Immunodeficiency disorders and autoimmune illnesses are ailments that have varying effects on the immune system. Immunodeficiency diseases develop when the immune system is unable to operate effectively, making people more vulnerable to infections and other ailments. In contrast, autoimmune disorders develop when the immune system erroneously assaults the body's own tissues and organs.

As the frequency of both of these disorders rises globally, there is a rising desire for effective therapies that can help people manage their symptoms and enhance their quality of life. Intravenous immunoglobulin (IVIG) is one such medication that has recently gained popularity due to its capacity to modify the immune system and give relief from a variety of autoimmune and immunodeficiency conditions.

IVIG is a blood product that includes antibodies taken from healthy donors' plasma. These antibodies have the potential to enhance the immune system and slow the course of some illnesses. IVIG is usually given intravenously and has been demonstrated to be beneficial in treating a variety of conditions, including primary immunodeficiency, autoimmune diseases, and neurological disorders.

As the frequency of immunodeficiency disorders and autoimmune illnesses rises, so does the need for IVIG and other immunoglobulin products. This has resulted in considerable expansion in the global IVIG market, with industry participants investing extensively in R&D to generate better, more effective treatments that can satisfy the demands of patients globally. Finally, the rising frequency of immunodeficiency disorders and autoimmune illnesses is propelling the IVIG market, as patients seek effective therapies to manage their symptoms and enhance their quality of life.

Expanding Applications of IVIG in Neurological and Inflammatory Disorders Will Generate Surplus Worldwide Intravenous Immunoglobulin Market Opportunities

IVIG is generally used to treat immunodeficiency disorders and autoimmune illnesses. However, there has been an increase in research on the use of IVIG for treating neurological and inflammatory illnesses in recent years, representing a substantial market opportunity for IVIG.

IVIG has been used to treat neurological illnesses such as Guillain-Barré Syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, and multifocal motor neuropathy. IVIG reduces inflammation and modulates the immune system, which can help to alleviate the symptoms of various illnesses.

Similarly, IVIG has been investigated for its potential application in the treatment of inflammatory illnesses such as rheumatoid arthritis, lupus, and psoriasis. Because IVIG has anti-inflammatory qualities, it is an appealing therapeutic option for these disorders because it can help to decrease inflammation in the afflicted tissues and organs.

Overall, as more patients seek effective therapies for neurological and inflammatory illnesses, the rising uses of IVIG create a considerable market potential. This has resulted in increased investment in IVIG and other immunoglobulin products focused at treating neurological and inflammatory illnesses. As a result, the intravenous immunoglobulin (IVIG) market is likely to expand during the next few years.

Intravenous Immunoglobulin Market Segmentation

The global market has been categorized into product, application, distribution channel, and regions

• The product segment is divided into IGG, IGA, IGM, IGE, and IGD
• The application segment is split into chronic inflammatory demyelinating polyneuropathy, chronic lymphocytic leukemia & myasthenia gravis, congenital AIDS & multifocal motor neuropathy, guillain-barre syndrome, hypogammaglobulinemia, immune thrombocytopenia (ITP), immunodeficiency diseases, kawasaki disease, and others
• The distribution channel segment is sub-divided into hospital pharmacy, specialty pharmacy, and others
• The market is divided into five regions that are North America, Latin America, Europe, Asia-Pacific, and The Middle East and Africa (MEA)

Intravenous Immunoglobulin Market Share

According to the intravenous immunoglobulin market forecast, the IGG product type sub-segment will have the most market share between 2023 and 2032.

According to the automated door industry analysis, the immunodeficiency illnesses application accounted for a sizable market share in 2022 and is expected to do so in the future.

Based on intravenous immunoglobulin (IVIG) market’s distribution channels, the hospital pharmacy gathered utmost market share in 2022 and is expected to do so in the coming years.

Intravenous Immunoglobulin Market Regional Outlook

North America, particularly the United States, is a significant market for IVIG. The region has a well-established healthcare system, high healthcare expenditure, and a large patient population. The prevalence of autoimmune diseases, primary immunodeficiency disorders, and neurological conditions drives the demand for IVIG. Additionally, favorable reimbursement policies and the presence of key market players contribute to the growth of the IVIG market in North America

The Asia Pacific region presents significant growth potential for the IVIG market. Countries like China, Japan, and India have large populations and a rising incidence of immunodeficiency disorders. Increasing healthcare spending, improving healthcare infrastructure, and expanding access to advanced therapies contribute to market growth in the region. However, pricing pressures, regulatory complexities, and limited awareness about IVIG therapy among healthcare professionals can be obstacles in certain countries.

Intravenous Immunoglobulin Market Players

Some prominent intravenous immunoglobulin companies covered in the industry include Baxter International, Inc., Bayer AG, Biotest AG (Tiancheng International Investment Limited), CSL Limited (CSL Behring), Grifols, S.A., Kedrion S.p.A, LFB S.A., Octapharma AG, and Takeda Pharmaceutical Company Limited.

Intravenous Immunoglobulin Business Strategies

• In February 2023, Grifols has announced the acquisition of Tiancheng International Investment Limited's blood transfusion diagnostics business in China, which includes production and commercial activities. This strategic purchase intends to boost Grifols' position in the Chinese market and broaden its diagnostic solution range.
• In January 2023, Baxter announced the launch of its new formulation of intravenous immunoglobulin (IVIG) therapy, called GAMUNEX®-C Liquid, in the United States. GAMUNEX®-C Liquid is a ready-to-use liquid IVIG formulation that provides healthcare practitioners with convenience and ease of administration.

Click here to buy the Premium Market Research report https://www.acumenresearchandconsulting.com/buy-now/0/3269

Receive our personalized services and customization by clicking here https://www.acumenresearchandconsulting.com/request-customization/3269

Mr. Frank Wilson

Acumen Research and Consulting

USA: +13474743864

India: +918983225533

E-mail: sales@acumenresearchandconsulting.com